Skip to main content

Table 5 QoL and symptom response rates among objective tumour responders and nonresponders

From: Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

Items

Responders (n = 11)

Nonresponders (n = 14)

p value

 

n

%

n

%

 

QoL

     

   Global QoL

10

91

4

29

0.004

   PF

10

91

7

50

0.042

   RF

10

91

5

36

0.012

   EF

11

100

11

79

0.23

   CF

10

91

8

57

0.09

   SF

10

91

6

43

0.033

Symptoms

     

   dyspnoea

9

82

5

36

0.021

   coughing

10

91

7

50

0.042

   haemoptysis

11

100

10

71

0.105

   appetite loss

11

100

9

64

0.046

   fatigue

8

73

3

21

0.01

  1. QoL, quality of life; PF, physical functioning; RF, role functioning; EF, emotional functioning; CF, cognitive functioning; SF, social functioning
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us